StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc.

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3048% below fair value
$143.82−4.00 (-2.71%)

Close on Nov 20, 2026Market cap $19.26BP/E 7.5Yield –

Alnylam Pharmaceuticals Net Cash Provided by Financing Activities

Net Cash Provided by Financing Activities ($M)

Alnylam Pharmaceuticals Net Cash Provided by Financing Activities: $18.4M in Q3 2026, down 104.4% from a year earlier.

Latest, Q3 2026
18.4
Period ended Sep 30, 2026
Change on a year earlier
-104.4%
-420 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
39
Documents cited below

Where the Q3 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Alnylam Form 10-Q (filed 2026-10-29) ↗

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Cash Provided by Financing Activities ($M)Year on yearSource
Q3 2026Sep 30, 202618.4-104.4%Alnylam Form 10-Q (filed 2026-10-29) ↗
Q2 2026Jun 30, 202636.2-53.4%Alnylam Form 10-Q (filed 2026-07-30) ↗
Q1 2026Mar 31, 202615.7-65.9%Alnylam Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025-8.90-128.7%Alnylam Form 10-Q (filed 2026-10-29) ↗
Q3 2025Sep 30, 2025-420-508.7%Alnylam Form 10-Q (filed 2026-10-29) ↗
Q2 2025Jun 30, 202577.7-40.9%Alnylam Form 10-Q (filed 2026-07-30) ↗
Q1 2025Mar 31, 202546.1+59.5%Alnylam Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 202431-20.9%Alnylam Form 10-K (filed 2025-02-13) ↗
Q3 2024Sep 30, 2024103+210.6%Alnylam Form 10-Q (filed 2024-10-31) ↗
Q2 2024Jun 30, 2024132+146.3%Alnylam Form 10-Q (filed 2024-08-01) ↗
Q1 2024Mar 31, 202428.9-37.7%Alnylam Form 10-Q (filed 2024-05-02) ↗
Q4 2023Dec 31, 202339.2-38.2%Alnylam Form 10-K (filed 2024-02-15) ↗
Q3 2023Sep 30, 202333.1-88.9%Alnylam Form 10-Q (filed 2023-11-02) ↗
Q2 2023Jun 30, 202353.4+76.2%Alnylam Form 10-Q (filed 2023-08-03) ↗
Q1 2023Mar 31, 202346.4+32.6%Alnylam Form 10-Q (filed 2023-05-04) ↗
Q4 2022Dec 31, 202263.4-78.3%Alnylam Form 10-K (filed 2023-02-23) ↗

Cite this data

StockData. (2026). Alnylam Pharmaceuticals Net Cash Provided by Financing Activities ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Alnylam Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/alny/kpis/db-financing-cf

See every metric in the Alnylam Pharmaceuticals KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?